CAT's Trading Like It's Nvidia. It's Not. Here's the Math.
At $520, you're not buying strength — you're buying hope.
AbbVie: Boring Business, Beautiful Cash Flow
AbbVie survived the Humira patent cliff everyone feared. Now at single-digit P/E with $22B in free cash flow and a 3% yield, you're paying for pharma discipline while others chase biotech moonshots. Sometimes boring wins.
Chevron: Built for Cash, Not Clicks
Chevron survived the Hess deal distraction. Now at $153 with 80% upstream margins and FCF covering dividends 1.7x, you're paying for discipline at 16.5× earnings. Guyana's $35 breakevens change everything. Target: $170 by 2027.
5 Dividend Kings Paying Over 3% in 2025
Five Dividend Aristocrats yielding over 3% that prove high income doesn’t have to mean high risk in 2025’s volatile market.
Tesla, Inc. (NASDAQ: TSLA): Priced for Perfection, Delivering Automaker Economics
Tesla is still the world’s most exciting car company. But at $440 a share, investors aren’t buying cars—they’re buying science fiction.
$JNJ: Dividend King or Lawsuit Trap?
JNJ isn’t broken.
But at $188, you’re paying growth multiples for a dividend stock with unlimited liability.
That’s not prudent — that’s hopeful.
The Costco Thesis
Bottom line: the fees pay for low prices, and low prices keep members hooked. My $1,200-$1,300 target for Costco by 2028.
Dividend Yield vs. Dividend Growth: Which Strategy Wins?
Dividend yield gives you cash now, dividend growth builds wealth later. Here’s how to weigh both strategies, avoid traps, and choose dividend stocks that deliver — not disappoint.
How to Identify Growth Stocks
Growth stocks can supercharge your portfolio—but only if you separate rockets from wrecks. This guide shows you how to use revenue growth, P/E, P/S, and market trends to spot winners, avoid traps, and master growth investing strategies.
Microsoft vs Apple: The Data That Shows Who's Still a Growth Stock
Microsoft still meets key growth stock criteria. Apple falls short. Here’s the data and what it means for your portfolio.